Epidemiology of Non-Alcoholic Fatty Liver Disease
The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The prevalence of NAFLD in the general population of Western countries is 20–30%. About 2–3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma. As a rule, the prevalence of NAFLD is higher in males and increases with increasing age, and it is influenced by the diagnostic method and the characteristics of the population, especially lifestyle habits. Population-based studies provide better estimates of the prevalence of NAFLD as compared to autoptic and clinical studies, but few such studies have been performed to date. The diagnosis of NAFLD in population studies is usually obtained by ultrasonography, which is known to underestimate the prevalence of fatty liver. The Dallas Heart Study and the Dionysos Study reported that 30% of the adults in the USA and 25% in Italy have NAFLD. In these studies, 79% and 55% of patients with NAFLD had normal aminotransferase levels, showing that liver enzymes are not surrogate markers of NAFLD in the general population. Noninvasive markers such as the fatty liver index obtained from the Dionysos Study may be useful to screen for NAFLD in the general population. The most important risk factors for NAFLD are male gender, age, obesity, insulin resistance and the cardiometabolic alterations that define the metabolic syndrome. The prevalence of NAFLD is 80–90% in obese adults, 30–50% in patients with diabetes and up to 90% in patients with hyperlipidemia. The prevalence of NAFLD among children is 3–10%, rising up to 40–70% among obese children. Moreover, pediatric NAFLD increased from about 3% a decade ago to 5% today, with a male-to-female ratio of 2:1. The incidence and natural history of NAFLD are still not well defined, but it is recognized that the majority of individuals with NAFLD do not develop NASH. The incidence of NAFLD is probably increasing in Western countries, strictly linked to lifestyle habits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of NAFLD among normal-weight children is 3–10%, rising up to 40–70% among obese children”
From Lack of Exercise Is a Major Cause of Chronic Diseases (2012) · cites this paper as [33]
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352 · cited 1×
“In the literature, many competing definitions of the MS are available. The definition recently put forth by the International Federation for the Study of Diabetes (IDF) [”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“It is important to note that this prevalence is partly dependent upon the method used to diagnose FL, the method used to assess alcohol intake and the cutoff point used to exclude ‘relevant’ alcohol intake, see table 2 , with respective references [ , , , , , , , , , , , , , , , , , , , , , ,”
MethodNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“] and 15p in Asian countries [ , , , , , , , , , ,”
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 1×
“We suggest to expand the number of prospective cohort studies in the general population, even if they are more expensive and difficult to handle, because they give more reliable results about the burden of disease attributable to NAFLD. The most simple, noninvasive and practical method for diagnosing FL in population…”
BackgroundSelf-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Population and clinical studies have increasingly shown that most cases of NAFLD are associated with the metabolic syndrome (MS), so that NAFLD is presently considered the hepatic manifestation of MS [”
BackgroundNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 1×
“Definition and Classification of Non-Alcoholic Fatty Liver DiseaseNon-alcoholic fatty liver disease (NAFLD) is operationally defined as fatty liver (FL), i.e. an accumulation of lipids inside the hepatocytes exceeding 5p of the weight of the liver, without hepatitis B virus or hepatitis C virus infection and in the ab…”
BackgroundIndependent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610 · cited 1×
“A recent study showed that 27p of US adults have raised levels of liver enzymes and that 79p of these values cannot be explained by the most common causes of liver disease [ , , , , , , , ,”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568 · cited 1×
“While steatosis is usually associated with a benign prognosis, steatohepatitis and fibrosis may progress to cirrhosis and possibly hepatocarcinoma.During the last decade, the number of studies on NAFLD has grown exponentially, and new concepts have been acquired by the scientific community. We now know that NAFLD is o…”
Background
Research works printed but not linked: 7
- 10.1097%2f00005176-200001000-00017 · doi:10.1097/00005176-200001000-00017 · Paper page
- 10.1016%2fs1590-8658%2802%2980194-3 · DOI
- 10.1111%2fj.1572-0241.2001.04052.x · doi:10.1111/j.1572-0241.2001.04052.x · Paper page
- 10.1016%2fs0168-8278%2801%2900094-0 · DOI · Paper page
- 10.1111%2fj.1572-0241.1999.01451.x · doi:10.1111/j.1572-0241.1999.01451.x · Paper page
- 10.3109%2f00365527709181339 · DOI · Paper page
- 10.1053%2fgast.2001.25540 · DOI · Paper page
Cited by
Items 501–600 of 1,000
Roy, S., Saha, P., Bose, D., Trivedi, A., More, M., Xiao, S., Diehl, A. M., & Chatterjee, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216354 · Cited by 23
“Globally, the spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD) related illness is steadily rising; about 38% of the adult population suffers from it [1–3].”
BackgroundRusli, F., Boekschoten, M. V., Zubia, A. A., Lute, C., Müller, M., & Steegenga, W. T. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400621 · Cited by 20
“Therefore, the increasing prevalence of metabolic syndrome and NAFLD becomes a major concern [5,6] and implies an urgent need for a feasible and effective dietary intervention to prevent NAFLD [7].”
BackgroundPrevalence of Metabolic Syndrome According to Different Definitions in a Hypertensive Population
Lioudaki, E., Vrentzos, G. E., Mavrogeni, H., Zeniodi, M.-H., Ganotakis, E. S., Mikhailidis, D. P., & Papadakis, J. A. (2011) · Angiology · doi:10.1177/0003319711407303 · Cited by 22
Influence of Plasma Cortisol and Other Laboratory Parameters on Nonalcoholic Fatty Liver Disease
Hubel, J., Schmidt, S. A., Mason, R., Haenle, M. M., Oeztuerk, S., Köenig, W., Boehm, B. O., Kratzer, W., Graeter, T., Flechtner‐Mors, M., et al. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1389982 · Cited by 24
Kim, S. R., Je, J., Jeong, K., Kim, S. J., Lee, K., Choi, S., Kim, H., & Park, S. W. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2018.4226 · Cited by 21
Selladurai, S., & Thittai, A. K. (2018) · Ultrasonics · doi:10.1016/j.ultras.2018.10.007 · Cited by 21
Ünsal, İ. Ö., Çalapkulu, M., Sencar, M. E., Çakal, B., & Özbek, M. (2022) · Scientific Reports · doi:10.1038/s41598-021-04361-x · Cited by 25
Nonalcoholic Fatty liver disease and psoriasis: what a dermatologist needs to know.
Prussick, R. B., Prussick, L., & Nussbaum, D. (2015) · Europe PMC (PubMed Central) · Cited by 35
Ikuta, T., Kanno, K., Arihiro, K., Matsuda, S., Kishikawa, N., Fujita, K., & Tazuma, S. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00920.x · Cited by 21
Relationship of Serum Betatrophin with Nonalcoholic Fatty Liver in a Chinese Population
Hu, W., Shao, X., Guo, D., Hao, H., Zhang, Y., Xia, M., Gong, Y., Zhou, H., Fan, Y.-Q., & Yu, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170758 · Cited by 22
Tran, B. V., Ujita, K., Taketomi-Takahashi, A., Hirasawa, H., Suto, T., & Tsushima, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255768 · Cited by 20
“The prevalence of NAFLD varies with age, gender, and weight status [5].”
BackgroundNon-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology
Akter, S. (2022) · Middle East Journal of Digestive Diseases · doi:10.34172/mejdd.2022.270 · Cited by 27
Barbhuiya, P. A., Sen, S., & Pathak, M. P. (2023) · Phytochemistry Reviews · doi:10.1007/s11101-023-09912-w · Cited by 24
“Since 47% of NAFLD patients are sure to develop NASH, the early stage of the disease appears as simple hepatic steatosis with a fat content that exceeds 5–10% of liver weight (Bellentani et al. 2010; Pais et al. 2013).”
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori
Abenavoli, L., Milić, N., Masarone, M., & Persico, M. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.08.011 · Cited by 20
“[3].”
van Meer, S., van Erpecum, K. J., Sprengers, D., Klümpen, H., Jansen, P. L. M., IJzermans, J. N. M., Siersema, P. D., de Man, R. A., & Verheij, J. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000641 · Cited by 21
“Moreover, available data suggest an overall prevalence rate of NAFLD between 20 and 40%, whereas in speci fi c subgroups, such as obese adults or patients with diabetes, the prevalence is even higher [27 – 30].”
Lim, J. Y., Liu, C., Hu, K., Smith, D. E., Wu, D., Lamon‐Fava, S., Ausman, L. M., & Wang, X. (2019) · Journal of Nutrition · doi:10.1093/jn/nxz106 · Cited by 20
Lü, H., Lei, X., Guo, S., Winkler, R., John, S., Kumar, D., Li, W., & Alnouti, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01654-6 · Cited by 20
Rasul, S., İlhan, A., Schernthaner-Reiter, M. H., Baumgartner-Parzer, S. M., & Kautzky‐Willer, A. (2011) · Gender Medicine · doi:10.1016/j.genm.2011.01.004 · Cited by 22
Hsiao, P., Chen, Z.-C., Hung, W., Yang, Y., Lee, M., Huang, J., & Kuo, K. (2013) · BMC Medical Genetics · doi:10.1186/1471-2350-14-54 · Cited by 21
Novel circulating biomarkers for non‐alcoholic fatty liver disease: A systematic review
Sahebkar, A., Sancho, E., Abelló, D., Camps, J., & Joven, J. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25779 · Cited by 26
“assume no genetic differences in the background of our patients (Bellentani et al., 2010) consequently we have done the systematic review focused on serum biomarkers.”
BackgroundAltered lipid metabolism and the development of metabolic-associated fatty liver disease
Foster, C., Gagnon, C. A., & Ashraf, A. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000933 · Cited by 19
Fatty Liver Index is a valid predictor of non-alcoholic fatty liver disease (NAFLD) in pregnancy
Koralegedara, I. S., Warnasekara, J. N., Rathnayake, A., Dayaratne, K. G., & Agampodi, S. B. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2022-000913 · Cited by 20
Chabanova, E., Bille, D. S., Thisted, E., Holm, J., & Thomsen, H. S. (2012) · Abdominal Imaging · doi:10.1007/s00261-012-9930-2 · Cited by 19
Non-alcoholic steatohepatitis: An update in pathophysiology, diagnosis and therapy
Khedmat, H., & Taheri, S. (2011) · Hepatitis Monthly · Cited by 23
Classification of Nonalcoholic Fatty Liver Texture Using Convolution Neural Networks
Reddy, D. S., Bharath, R., & Rajalakshmi, P. (2018) · IEEE International Conference on e-Health Networking, Applications and Services (Healthcom) · doi:10.1109/healthcom.2018.8531193 · Cited by 22
Efficacy of Artemisia annua L. extract for recovery of acute liver failure
Park, C. Y., Choi, E.-Y., Yang, H., Ho, S., Park, S., Park, K., & Kim, S. (2020) · Food Science & Nutrition · doi:10.1002/fsn3.1662 · Cited by 20
“The prevalence of NASH is about 2%–5% worldwide (Bellentani et al., 2010) and about 2% in Korea (Lee et al., 2007).”
BackgroundAdipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19
Cordeiro, A., Ribamar, A., & Ramalho, A. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101807 · Cited by 21
“Remarkably, MAFLD is a chronic dysmetabolic pandemic which has become the most common liver disease worldwide, with a high prevalence in the population with obesity [22,23].”
Theel, W. B., Klerk, B. M. B., Dirksmeier-Harinck, F., van Rossum, E. F. C., Kanhai, D. A., Apers, J. A., van Dalen, B. M., de Knegt, R. J., Holleboom, A. G., Tushuizen, M. E., et al. (2022) · Obesity Reviews · doi:10.1111/obr.13481 · Cited by 22
“21 11,22 – 24 Hence, the term “ metabolic dysfunction-associated fatty liver disease ” (MAFLD) has been proposed.”
BackgroundAssociation between Mediterranean Diet and Fatty Liver in Women with Overweight and Obesity
Leone, A., Bertoli, S., Bedogni, G., Vignati, L., Pellizzari, M., & Battezzati, A. (2022) · Nutrients · doi:10.3390/nu14183771 · Cited by 20
“In Western countries, NAFLD affects 20–30% of the adult general population [5], with a prevalence higher in men than in women in the reproductive age.”
BackgroundSelf-citationZhang, L., Jin, Y., Jin, Q., Lin, L., Zhang, D., & Kong, L. (2013) · Gene · doi:10.1016/j.gene.2013.08.001 · Cited by 19
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease
Miller, M. H., Bradford, V., & Dillon, J. F. (2013) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s34472 · Cited by 21
1 H MRS Assessment of Hepatic Fat Content
Chabanova, E., Fonvig, C. E., Frithioff‐Bøjsøe, C., Holm, J., & Thomsen, H. S. (2017) · Academic Radiology · doi:10.1016/j.acra.2017.02.010 · Cited by 19
Sabater, A. G., Ribot, J., Priego, T., Vazquez, I., Frank, S., Palou, A., & Buchwald‐Werner, S. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477606 · Cited by 21
Wu, L., Yan, M., Jiang, J., He, B., Wei, H., & Chen, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.128 · Cited by 19
Hiwatashi, K., Ueno, S., Sakoda, M., Iino, S., Minami, K., Yamasaki, Y., Okubo, K., Noda, M., Kurahara, H., Mataki, Y., et al. (2015) · Journal of Cancer · doi:10.7150/jca.10398 · Cited by 18
“[16] Our examination showed a prevalence of 17.”
BackgroundNon-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship
Abenavoli, L., Renzo, L. D., Guzzi, P. H., Pellicano, R., Milić, N., & LORENZO, A. D. (2015) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-595 · Cited by 21
“NAFLD occurs in 60-95% of Introduction Non-alcoholic fatty liver disease (NAFLD) is a relevant issue in public health [1,2].”
Perez, G. S., dos Santos, L. S., Cordeiro, G. S., Paraguassú, G. M., Athanazio, D. A., Couto, R. D., Deiró, T. C. B. D. J., Manhães‐de‐Castro, R., & Medeiros, J. M. B. (2015) · PubMed · doi:10.3305/nh.2015.32.4.9607 · Cited by 18
Risk factors for liver disease among adults of Mexican descent in the United States and Mexico
Flóres, Y. N., Zhang, Z., Bastani, R., Leng, M., Crespi, C. M., Ramírez‐Palacios, P., Stevens, H. A., & Salmerón, J. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i37.4281 · Cited by 18
Ibacahe, C., Correa‐Burrows, P., Burrows, R. A., Barrera, G., Kim, E., Hirsch, S., Jofré, B., Blanco, E., Gahagan, S., & Bunout, D. C. (2020) · Diagnostics · doi:10.3390/diagnostics10060431 · Cited by 18
“It is closely associated with increasing obesity prevalence among adults; thus, it is rapidly becoming the most common liver disease worldwide [1].”
BackgroundNejati, L., Movahedi, A., Salari, G. R., Moeineddin, R., & Nejati, P. (2022) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.36.39 · Cited by 27
Osganian, S. A., Subudhi, S., Masia, R., Drescher, H. K., Bartsch, L. M., Chicote, M. L., Chung, R. T., Gee, D. W., Witkowski, E. R., Bredella, M. A., et al. (2022) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2022.101482 · Cited by 18
Bille, D. S., Chabanova, E., Gamborg, M., Fonvig, C. E., Nielsen, T. R. H., Thisted, E., Thomsen, H. S., & Holm, J. (2012) · Clinical Obesity · doi:10.1111/j.1758-8111.2012.00038.x · Cited by 18
“Paediatric fatty liver disease developing in the absence of alcohol intake, termed non-alcoholic fatty liver disease (NAFLD), is being recognized with the increasing prevalence of childhood obesity (1).”
BackgroundWater Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease
Tzanetakou, I. P., Doulamis, I. P., Κορού, Λ.-Μ., Agrogiannis, G. D., Vlachos, I. S., Pantopoulou, A., Mikhailidis, D. P., Patsouris, E., Vlachos, I. S., & Perrea, D. N. (2012) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401206010088 · Cited by 18
“In the US it affects 30% of adult population and 1 out of 10 children aged 1-19 years [6].”
BackgroundWang, Y., Li, J., Han, M., Wang, W., & Li, Y.-Z. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0082-6 · Cited by 18
Halmos, T., & Suba, I. (2017) · Orvosi Hetilap · doi:10.1556/650.2017.30936 · Cited by 21
Patel, V., Joharapurkar, A., Kshirsagar, S., Patel, M., Sutariya, B., Patel, H., Pandey, D., Patel, D., Ranvir, R., Kadam, S., et al. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2017-0683 · Cited by 17
Ebrahimi-Mousavi, S., Alavian, S. M., Sohrabpour, A. A., Dashti, F., Djafarian, K., & Esmaillzadeh, A. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02176-2 · Cited by 17
“The general prevalence of NAFLD, based on ultrasound screening, is estimated to be 20–30% [3].”
BackgroundLange, U. G., Moulla, Y., Schütz, T., Blüher, M., Peter, V., Shang, E., & Dietrich, A. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06180-z · Cited by 18
Ferrer, M. D., Reynés, C., Monserrat-Mesquida, M., Quetglas‐Llabrés, M. M., Bouzas, C., García, S., Mateos, D., Casares, M., Gómez, C., Ugarriza, L., et al. (2023) · Antioxidants · doi:10.3390/antiox12030711 · Cited by 19
Orcel, T., Chau, H. T., Turlin, B., Chaigneau, J., Bannier, É., Otal, P., Frampas, É., Leguen, A., Boulic, A., Saint‐Jalmes, H., et al. (2023) · European Radiology · doi:10.1007/s00330-023-09798-4 · Cited by 18
Chhimwal, J., Dhritlahre, R. K., Anand, P., Ruchika, Patial, V., Saneja, A., & Padwad, Y. S. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213627 · Cited by 17
Festi, D., Schiumerini, R., Marasco, G., Scaioli, E., Pasqui, F., & Colecchia, A. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1049155 · Cited by 17
“The prevalence of the disease is rapidly increasing worldwide, along with an increase in its main risk factors, such as obesity and Type 2 diabetes [2].”
BackgroundThe effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice
Gamliel-Lazarovich, A., Raz‐Pasteur, A., Coleman, R., & Keidar, S. (2013) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328360554a · Cited by 17
Lin, S., Xian, Y.-J., Liu, Y., Cai, W., Song, J., & Zhang, X. (2018) · Medicine · doi:10.1097/md.0000000000010021 · Cited by 17
Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC
Zhao, F. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_7 · Cited by 18
Role of gut microbiota in the development of non-alcoholic fatty liver disease
Wang, X., Xia, J., & Jiang, C. (2019) · Liver Research · doi:10.1016/j.livres.2019.01.006 · Cited by 17
Mumtaz, S., Schomaker, N., & Roenn, N. V. (2019) · Clinical Liver Disease · doi:10.1002/cld.750 · Cited by 17
Mikolašević, I., Žanko, V. L., Jakopčić, I., Domislović, V., Mijić, A., Stevanović, T., Delija, B., Bokun, T., Kujundžić, P. D., Ostojić, Z., et al. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107512 · Cited by 18
Liver abnormalities in Turner syndrome: the importance of estrogen replacement
Fedor, I., Zold, E., & Barta, Z. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac124 · Cited by 16
“We should emphasize that, particularly, NAFLD is on the rise recently because the consumption of spirits was decreasing before the recent COVID-19 pandemic [51, 52].”
BackgroundOmidkhoda, N., Mahdiani, S., Hayes, A. W., & Karimi, G. (2023) · Phytotherapy Research · doi:10.1002/ptr.8020 · Cited by 16
Covelli, D., Vannucchi, G. M., Campi, I., Currò, N., D’Ambrosio, R., Maggioni, M., Gianelli, U., Beck‐Peccoz, P., & Salvi, M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4463 · Cited by 16
Luo, K., Bian, J., Wang, Q., Wang, J., Chen, F., Li, H., & Jin, D. (2019) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2019.18343 · Cited by 17
“NAFLD is the most common cause of chronic liver disease in developed countries, with a prevalence from 7% to 33% (2).”
BackgroundHepatocellular carcinoma and metabolic syndrome: The times are changing and so should we
Tsoulfas, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3842 · Cited by 18
Hong, Y., Choi, S., Hong, E., & Kim, G. (2020) · Journal of Food Science · doi:10.1111/1750-3841.15166 · Cited by 16
Bimro, E. T., Hovav, R. H., Nyska, A., Assa-Glazer, T., & Madar, Z. (2020) · Food & Nutrition Research · doi:10.29219/fnr.v64.4278 · Cited by 18
“Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world, with disease incidence reaching 25–30% of the total population (10).”
BackgroundCML/RAGE Signal Bridges a Common Pathogenesis Between Atherosclerosis and Non-alcoholic Fatty Liver
Pang, Q., Sun, Z., Shao, C., Cai, H., Bao, Z., Wang, L., Li, L., Jing, L., Zhang, L., & Wang, Z. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.583943 · Cited by 17
“NAFLD is a disease characterized by dyslipidemia and impaired liver function (51).”
BackgroundWaghorn, P. A., Ferreira, D. S., Erstad, D. J., Rotile, N. J., Masia, R., Jones, C. M., Tu, C., Sojoodi, M., Chen, Y. I., Schlerman, F. J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85679-4 · Cited by 17
Mediterranean dietary pattern and non-alcoholic fatty liver diseases: a case-control study
Entezari, M. H., Talenezhad, N., Mirzavandi, F., Rahimpour, S., Mozaffari–Khosravi, H., Fallahzadeh, H., & Hosseinzadeh, M. (2021) · Journal of Nutritional Science · doi:10.1017/jns.2021.43 · Cited by 16
“Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide((1)).”
BackgroundMethodHüttl, M., Marková, I., Miklánková, D., Zapletalová, I., Poruba, M., Rácová, Z., Večeřa, R., & Malínská, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010045 · Cited by 17
“The prevalence of NAFLD is reported at 20–30% in the general population of Western countries and 30–50% in patients with T2DM [4].”
BackgroundHe, X., Jiang, J., & Zhang, X. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-19369-7 · Cited by 19
Caserta, C. A., Mele, A., Surace, P., Ferrigno, L., Amante, A., Messineo, A., Vacalebre, C., Amato, F., Baldassarre, D., Amato, M., et al. (2017) · Annali dell Istituto Superiore di Sanità · doi:10.4415/ann_17_01_14 · Cited by 16
“The prevalence in the general population has been estimated around 20-30% [3].”
BackgroundResultLiu, Y., Zhai, T., Yu, Q., Zhu, J. K., & Chen, Y. (2018) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2018.03.005 · Cited by 16
Eekelen, E. W.-V., Beulens, J. W. J., Geelen, A., Schrauwen‐Hinderling, V. B., Lamb, H. J., Roos, A., Rosendaal, F. R., & de Mutsert, R. (2018) · Journal of Nutrition · doi:10.1093/jn/nxy313 · Cited by 17
Pfirrmann, D., Haller, N., Huber, Y., Jung, P., Lieb, K., Gockel, I., Poplawska, K., Schattenberg, J. M., & Simon, P. D. (2018) · JMIR Research Protocols · doi:10.2196/resprot.8607 · Cited by 17
“There is a worldwide trend toward higher incidence of Barrett cancer [1-3], depression [4], or nonalcoholic fatty liver disease (NAFLD) [5-7], and an alarming increase in overweight and obesity [8].”
High Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation
Hernáez, R., & Thrift, A. P. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.05.002 · Cited by 16
“3% to 33% with a median of 20%, to close to 50-90% in high risk groups (dyslipidemia, diabetes and obesity)(2), in contrast to NASH, which is found in only 23% of the general population (3).”
BackgroundHan, K., Gao, L., Xu, H., Li, J., Han, L., Shen, J., Sun, W., & Gao, Y. (2024) · BMC Public Health · doi:10.1186/s12889-024-18189-3 · Cited by 15
“The LLOD for uGLY was 0.2 ng/ml. FLI was defined as the dependent variable, which had been validated as a valid tool for assessing NAFLD [21, 22]and was obtained by the following formula [36]: Fatty Liver Index (FLI) = (e 0.953 × Ln (TG) + 0.139 × BMI + 0.7 18 × Ln(GGT) + 0.053 × WC − 15.745) ÷ (1…”
MethodInfluentialSabzikarian, M., Mahmoudi, T., Tabaeian, S. P., Rezamand, G., Asadi, A., Farahani, H., Nobakht, H., Dabiri, R., Mansour‐Ghanaei, F., Derakhshan, F., et al. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1791187 · Cited by 17
“…have reported that patients with NAFLD are predisposed to metabolic disorders such as abnormal glucose tolerance (Haukeland et al. 2005), insulin resistance (IR) (Eguchi et al. 2006, Brunt et al. 2009), type-2 diabetes (T2D) (Bellentani et al. 2010), and obesity (Dietrich and Hellerbrand 2014).”
BackgroundTumor suppressor Menin acts as a corepressor of LXRα to inhibit hepatic lipogenesis
Cheng, P., Li, G., Yang, S. S., Liu, R., Jin, G., Zhou, X. Y., & Hu, X. G. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.04.049 · Cited by 15
Expert opinion on current therapies for nonalcoholic fatty liver disease
Corte, C. D., Alisi, A., Iorio, R. F., Alterio, A., & Nobili, V. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.587123 · Cited by 16
“The prevalence of NAFLD increases to 80 -- 90% in obese adults, 30 -- 50% in patients with type 2 diabetes and up to 90% in patients with hyperlipidemia [4].”
BackgroundImpact of anthropometric cut‐off values in determining the prevalence of metabolic alterations
Almeda‐Valdés, P., Aguilar-Salinas, C. A., Uribe, M., Canizales‐Quinteros, S., & Méndez‐Sánchez, N. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12672 · Cited by 15
Chang, S., Liu, X., Carlsson, N. P., Park, Y., Colditz, G. A., Garonzik‐Wang, J., Chapman, W. C., Wellen, J. R., Doyle, M. B. M., & Alhamad, T. (2017) · Transplantation Direct · doi:10.1097/txd.0000000000000681 · Cited by 15
“Because obesity is prevalent in the United States and other countries, the prevalence of nonalcoholic fatty liver disease is estimated to be 20% to 30% in western countries and 80% to 90% in obese adults.(47) Furthermore, 35.”
BackgroundAssociation of CTRP13 With Liver Enzymes and Cognitive Symptoms in Nonalcoholic Fatty Liver Disease
An, K., Starkweather, A. R., Sturgill, J., Salyer, J., & Sterling, R. K. (2018) · Nursing Research · doi:10.1097/nnr.0000000000000319 · Cited by 15
Li, T. T., Tan, T.-B., Hou, H. Q., & Zhao, X. Y. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0901-7 · Cited by 15
Kiluk, P., Baran, A. M., Kaminski, T. W., Maciaszek, M., & Flisiak, I. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122206 · Cited by 15
“Risk factors include male gender, age, obesity, IR, and MS [46].”
BackgroundSarkar, S., Lipworth, L. P., Kabagambe, E. K., Bian, A., Stewart, T. G., Blot, W. J., Ikizler, T. A., & Hung, A. M. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00071 · Cited by 15
“The prevalence of non-alcoholic fatty liver disease (NAFLD) is generally estimated to be 20–30% in Western countries (1).”
BackgroundHu, L., Shao, X., Qiu, C., Shao, X., Wang, X., Niu, R., & Wang, Y. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00556-x · Cited by 15
Khalatbari‐Soltani, S., Marques-Vidal, P. M., Imamura, F., & Forouhi, N. G. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040959 · Cited by 18
The prevalence of non-alcoholic fatty liver disease in healthy young persons
Karacaer, Z. (2016) · Northern Clinics of Istanbul · doi:10.14744/nci.2016.28199 · Cited by 15
“[20] showed that 79% and 55% of patients with NAFLD had normal ALT levels.”
BackgroundMonem, M. S. A., Adel, A., Abbassi, M., Abdelaziz, D. H., Hassany, M., Raziky, M. E., & Sabry, N. A. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102543 · Cited by 16
Duodenal jejunal bypass attenuates non-alcoholic fatty liver disease in western diet-obese rats
Ebertz, C. E., Bonfleur, M. L., Bertasso, I. M., Mendes, M. C., Lubaczeuski, C., Araujo, A. C. D. F., Paes, A. M. D. A., Porto, E. M., & Balbo, S. L. (2014) · Acta Cirúrgica Brasileira · doi:10.1590/s0102-8650201400150009 · Cited by 15
Pi, Z., Wang, M., Lin, H., Guo, Y., Chen, S., Diao, X., Xia, H., Liu, G., Zeng, J., Zhang, X., et al. (2021) · BioMedical Engineering OnLine · doi:10.1186/s12938-021-00879-3 · Cited by 16
“Nonalcoholic fatty liver disease (NAFLD) is a main cause of chronic liver disease (CLD) and is rapidly becoming one of the most common liver diseases, with an approximate prevalence of 20–30% of the total population in Western countries [1, 2].”
BackgroundMoradi, F., Heidari, Z., Teimouri, A., Ghazvini, M., Imani, Z. F., & Naeini, A. A. (2022) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_411_20 · Cited by 16
“The incidence of fatty liver is increasing in Western countries.[5] The disease depends on many factors including genetic, metabolic, environmental, microbial, and other factors and is strongly associated with lifestyle.”
BackgroundSalmi, A., di Filippo, L., Ferrari, C., Frara, S., & Giustina, A. (2022) · Endocrine · doi:10.1007/s12020-022-03157-x · Cited by 15
“One-third of patients with NAFLD is affected also by MetS, and 90% of NAFLD patients have at least one diagnostic MetS criteria [4, 8, 9].”
BackgroundGrzelka‐Woźniak, A., Uruska, A. A., Szymańska‐Garbacz, E., Araszkiewicz, A., Jabłkowski, M., Czupryniak, L., & Zozulińska‐Ziółkiewicz, D. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16404 · Cited by 17
Autoimmune liver disease - are there spectra that we do not know?
Fallatah, H. I., & Akbar, H. O. (2011) · Comparative Hepatology · doi:10.1186/1476-5926-10-9 · Cited by 15
Exercise Training as Treatment of Nonalcoholic Fatty Liver Disease
Glass, O., Radia, A., Kraus, W. E., & Abdelmalek, M. F. (2017) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk2040035 · Cited by 15
Nakamura, A., Yoneda, M., Sumida, Y., Eguchi, Y., Fujii, H., Hyogo, H., Ono, M., Suzuki, Y., Kawaguchi, T., Aoki, N., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12101 · Cited by 16
Hepato-splenic axis: hepatic and splenic metabolic activities are linked.
Keramida, G., Dunford, A., Kaya, G., Anagnostopoulos, C., & Peters, A. M. (2018) · Europe PMC (PubMed Central) · Cited by 21
Song, H., Mao, Z., Yang, L., Liu, T., Li, D., Zhang, L. R., Ying-li, G. E., Zheng, P., Liu, P., Zhang, X., et al. (2011) · 中医杂志:英文版 · doi:10.1016/s0254-6272(12)60013-2 · Cited by 13
Nutrition Interventions for Chronic Liver Diseases and Nonalcoholic Fatty Liver Disease
Pimentel, C. F. M. G., & Lai, M. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.06.010 · Cited by 15
Metadata
- Authors
- Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 28
- Issue
- 1
- Pages
- 155-161
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2036047239
- Cited by
- 1,026
- References
- 77
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 31 · 2023: 51 · 2022: 72 · 2021: 71 · 2020: 78 · 2019: 85 · 2018: 96 · 2017: 97 · 2016: 89 · 2015: 84 · 2014: 71 · 2013: 81 · 2012: 48
- FWCI
- 40.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, prevalence, nonalcoholic steatohepatitis, liver cirrhosis, hepatocellular carcinoma, risk factors, obesity, insulin resistance, metabolic syndrome, fatty liver index, NAFLD screening, pediatric NAFLD, incidence, lifestyle, transaminases
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Humans, Italy, Male, Middle Aged, Risk Factors, United States, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.